AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19766645
Drug: PegIFNalpha2b plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNalpha2b plus RBV 800-1200 mg/day
Trial: 9422572
Drug: 3.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 Gy daily fractions
Trial: 9422572
Drug: bio-average and
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bio-average and bio-maximum dose (corrected for fraction size)
Trial: 9422572
Drug: uncorrected dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: uncorrected dose distributions
Trial: 28328347
Drug: CSL830 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL830 40 IU/kg twice weekly
Trial: 28328347
Drug: CSL830 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL830 60 IU/kg twice weekly
Trial: 25833063
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (4 ml/kg body weight, 0.48 g/kg of alcohol 12%, corresponding to 2-3 glasses/daily) and extra-virgin olive oil (treatment A)
Trial: 25833063
Drug: Extra-virgin olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-virgin olive oil alone (treatment B)
Trial: 25833063
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine and extra-virgin olive oil (treatment A)
Trial: 23517291
Drug: Desvenlafaxine 10
RxNorm normalized name: desvenlafaxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 10 mg/day
Trial: 23517291
Drug: Desvenlafaxine 10
RxNorm normalized name: desvenlafaxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 10 mg/day and 50 mg/day
Trial: 16621868
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day ezetimibe (Group A)
Trial: 16621868
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day ezetimibe as an add-on to 20 mg/day simvastatin (Group B)
Trial: 16621868
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation from 10 to 40 mg/day atorvastatin (Group C)
Trial: 16621868
Drug: De novo
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De novo monotherapy with 40 mg/day atorvastatin (Group D)
Trial: 11371418
Drug: Control oral
RxNorm normalized name: Dayquil Mucus Control Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oral plate (A)
Trial: 9296410
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 0, 25, 50, or 75 microg x kg(‐1) x min(‐1)
Trial: 9296410
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 50-75 microg x kg(‐1) x min(‐1)
Trial: 9296410
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion of 25-50 microg x kg(‐1) x min(‐1) in combination with alfentanil infusion of 0.2-0.4 microg x kg(‐1) x min(‐1)
Trial: 8289986
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g elemental calcium per day
Trial: 29417623
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 g daily)
Trial: 24507630
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) for PTSD (n = 30)
Trial: 24507630
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (n = 29)
Trial: 20854144
Drug: etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etravirine 200 mg twice-daily
Trial: 17646601
Drug: UFH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH dosage of 5000 U 3 times daily
Trial: 10665629
Drug: Paroxetine (20‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20‐60 mg/day)
Trial: 10665629
Drug: Clomipramine (50‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (50‐150 mg/day)
Trial: 10665629
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (12 sessions)
Trial: 8690817
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours for 8 days) after a standardized 602-calorie, high-fat breakfast
Trial: 8690817
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours for 8 days) after an overnight fast
Trial: 2060542
Drug: Simvastatin 30
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 30 mg/day
Trial: 6196822
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 (1000-1500 ml) with Ringer's acetate solution (2000-3000 ml)
Trial: 6196822
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate alone (5000-8000 ml)
Trial: 2492325
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA, 150 mg/8 h)
Trial: 2492325
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients with intracoronary thrombus
Trial: 2492325
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients without thrombus
Trial: 29978790
Drug: rESWT (radial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rESWT (radial extracorporeal shockwave therapy) for 1 cycle
Trial: 29978790
Drug: Local hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local hormone injection for 1 cycle
Trial: 25087182
Drug: Asparaginase and
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asparaginase and steroids
Trial: 25087182
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of asparaginase and steroids
Trial: 25087182
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of ALL therapy
Trial: 20636856
Drug: Magnetic film
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic film array application of 5% urea gel
Trial: 20636856
Drug: Passive occluded
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive occluded application of 5% urea gel with plastic occlusive film and non-magnetic film
Trial: 15745837
Drug: Postprandial strategy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial strategy: premeal insulin lispro with basal insulin at bedtime (NPH insulin), targeting 2‐h PPBG < or = 7.5 mmol/l
Trial: 15745837
Drug: Basal strategy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal strategy: insulin (NPH insulin twice daily or insulin glargine once daily; or premixed human insulin (70% NPH/30% regular; 30/70) twice daily), targeting fasting and premeal blood glucose (BG; < or = 6.7 mmol/l)
Trial: 2268486
Drug: HD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD with a sodium profile (140‐148 mmol/L)
Trial: 2268486
Drug: Conventional HD
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional HD (dialysate sodium 140 mmol/L)
Trial: 31915861
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of CBD for 1 week
Trial: 25261342
Drug: Opioid antagonist
RxNorm normalized name: OPIOID ANTAGONIST ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid antagonist (50 mg naltrexone)
Trial: 20443645
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of pharmacotherapy and psychotherapy
Trial: 20443645
Drug: Clinical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical management and treatment as usual
Trial: 17876994
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine
Trial: 17876994
Drug: Fluvoxamine, paroxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine, paroxetine, and sertraline (SSRIs available in Japan)
Trial: 16128368
Drug: Aprotinin (15,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (15,000 KIU/min) administered in the pulmonary artery
Trial: 10566553
Drug: RCP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCP level > or = 1.0 ng/ml
Trial: 2006653
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg plus Amiloride 2.5 mg
Trial: 27003595
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (PFMT) over 3 months (12 weekly sessions)
Trial: 27003595
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no specific LUTS treatment)
Trial: 24731890
Drug: 6-week stress
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week stress management programme (relaxation breathing and progressive muscle relaxation, RB-PMR, twice a day) (N=31)
Trial: 20655946
Drug: Project Towards
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Project Towards No Drug Abuse (TND) program with regular workshop training
Trial: 20655946
Drug: Project Towards
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Project Towards No Drug Abuse (TND) program with comprehensive implementation support
Trial: 17434541
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg cinnarizine (CIN)
Trial: 11956258
Drug: ECF (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECF (epirubicin 50 mg/m(2) every 3 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 200 mg/m(2)/d)
Trial: 11956258
Drug: MCF (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCF (mitomycin 7 mg/m(2) every 6 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 300 mg/m(2)/d)
Trial: 9708225
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day etidronate for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Trial: 9708225
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Trial: 29911321
Drug: Fractional CO2-laser
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2-laser treatment (two sessions in a 4-week interval)
Trial: 29911321
Drug: Fractional CO2-laser
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2-laser treatment
Trial: 28901116
Drug: Tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium glycosides combined with Danshen injection
Trial: 20137366
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with sufentanil 0.5 microg/ml
Trial: 20137366
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with sufentanil 0.5 microg/ml
Trial: 20137366
Drug: Levobupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine with sufentanil 0.5 microg/ml
Trial: 10554373
Drug: Short-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course antibiotic therapy (24 hours)
Trial: 10554373
Drug: Long-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course antibiotic therapy (5 days)
Trial: 8556837
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta administered subcutaneously either daily or thrice weekly
Trial: 1789812
Drug: Simvastatin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (2.5 to 40 mg q.p.m.)
Trial: 7326162
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl anaesthesia (75 micrograms kg‐1)
Trial: 7326162
Drug: Incremental doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental doses of papaveretum
Trial: 28384752
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of NP001
Trial: 26513587
Drug: alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcohol (0.8 g/kg)
Trial: 26513587
Drug: delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: delta-9-tetrahydrocannabinol (THC) (7.5 mg)
Trial: 19699834
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily energy intake
Trial: 9754848
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tolperisone hydrochloride
Trial: 9754848
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tolperisone hydrochloride
Trial: 579654
Drug: Holoxan therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holoxan therapy
Trial: 30221615
Drug: DREAMS-START intervention
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DREAMS-START intervention (six-session manualized therapy)
Trial: 24033650
Drug: Computerized aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized aphasia therapy
Trial: 21876444
Drug: Crushed lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed lopinavir/ritonavir tablets (200/50 mg)
Trial: 21876444
Drug: Whole lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole lopinavir/ritonavir tablets (200/50 mg)
Trial: 19682886
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 50 microg
Trial: 19682886
Drug: SYS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYS group (Intravenous fentanyl 50 microg)
Trial: 16939523
Drug: PEG‐Intron 3‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐Intron 3‐6 microg kg(‐1) administered subcutaneously once a week
Trial: 15472204
Drug: Canrenoate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenoate (200 mg injections)
Trial: 11576570
Drug: Norethindrone-containing pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone-containing pills
Trial: 11576570
Drug: Desogestrel-containing pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing pills
Trial: 3503390
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of OK-432 (ID Group)
Trial: 3503390
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of OK-432 (IM Group)
Trial: 31388792
Drug: AT-101 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (150 mg/m2) and carboplatin (AUC 5) at DL1
Trial: 31388792
Drug: AT-101 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (175 mg/m2) and carboplatin (AUC 6) at DL2
Trial: 26607848
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg total: two 40 mg capsules 1 hour prior to extraction and one 40 mg capsule postoperatively)
Trial: 26607848
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg total)
Trial: 24047916
Drug: High-Protein (HP)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Protein (HP) diet (≥90 g protein/d)
Trial: 19515530
Drug: 1% ISDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ISDN in Vaseline applied to the dorsum of the affected hand four times daily for 10 weeks
Trial: 19515530
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied to the dorsum of the affected hand four times daily for 10 weeks
Trial: 15220683
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids (specifics not detailed)
Trial: 15220683
Drug: Therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids
Trial: 11069315
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for active ulcerative colitis
Trial: 11069315
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to treatment
Trial: 2866830
Drug: Dezocine 15
RxNorm normalized name: dezocine 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 15 mg
Trial: 30548692
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg/day plus solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg (with potential to double the antimuscarinic dose at week 8)
Trial: 30548692
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg/day plus antimuscarinic therapy
Trial: 30548692
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg/day plus propiverine
Trial: 30548692
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg/day plus tolterodine
Trial: 29450494
Drug: Clinical Treatment
RxNorm normalized name: Clinicalm
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clinical Treatment Score
Trial: 19558724
Drug: Speed of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speed of processing treatment
Trial: 19558724
Drug: Memory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory treatment
Trial: 19558724
Drug: Reasoning treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasoning treatment
Trial: 15225189
Drug: 600 micro
RxNorm normalized name: Fentanyl 600 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 micro g misoprostol sublingually
Trial: 15225189
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml syntometrine intravenously
Trial: 2681086
Drug: Anandron 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anandron 300 mg daily
Trial: 28946528
Drug: PNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNF treatment
Trial: 28946528
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MAN.T)
Trial: 23038624
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg for 1 week
Trial: 21804104
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily)
Trial: 21804104
Drug: Clopidogrel (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300-600 mg loading dose, 75 mg daily)
Trial: 19538732
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg/day, orally, for 12 months)
Trial: 9056681
Drug: Nisoldipine CC
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine CC 10 mg
Trial: 9056681
Drug: Nisoldipine CC
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine CC 20 mg